Entering text into the input field will update the search result below

Sanofi-Regeneron's Libtayo combo accepted for review by FDA for lung cancer subtype

Jan. 19, 2022 11:52 AM ETRegeneron Pharmaceuticals, Inc. (REGN) StockSNYBy: Ravikash Bakolia, SA News Editor

Human Respiratory System Lungs Anatomy

magicmine/iStock via Getty Images

  • The U.S. Food and Drug Administration (FDA) accepted to review Regeneron Pharmaceuticals (REGN +1.9%) and Sanofi's (SNY -0.2%) application seeking approval of Libtayo (cemiplimab-rwlc) in combination with chemotherapy as first-line treatment for advanced non-small

Recommended For You

More Trending News

About REGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
REGN--
Regeneron Pharmaceuticals, Inc.